Hansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs

MT Newswires Live

2025/04/08

Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.

Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.

HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2525897757"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525897757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525897757?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525897757","market":"sg","top_or_hot":-1,"title":"Hansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs","media":"MT Newswires Live","content":"<html><body><p> Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.</p><p>Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.</p><p>HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical Gets China Nod for Trial of Two Tumor Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-08 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.</p><p>Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.</p><p>HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525897757","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525897757","pubTimestamp":1744118056,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Two products of Hansoh Pharmaceutical Group  have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产"},"translate_title":"豪森药业两种肿瘤药物试验获得中国批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}